Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156

October 13, 2026
Read More
October 5, 2026

Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026

Read More
September 16, 2026

Sironax Announces Option Exercise and Asset Purchase

Read More
September 16, 2026

Sironax Announces Option Exercise & Asset Purchase of its Brain Delivery Platform: Perspectives from Dr. Shefali Agarwal, President & CEO

Watch Video
Learn More

Publications

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy adults and elderly participants

Clin Transl Sci., 2025

A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants

Clin Transl Sci., 2024

Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases

International Neurology & Brain Disorders Conference, 2024

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Journal of Intensive Medicine, 2024